Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Isabella Faraoni is active.

Publication


Featured researches published by Isabella Faraoni.


Biochimica et Biophysica Acta | 2009

miR-155 gene: a typical multifunctional microRNA.

Isabella Faraoni; Francesca Romana Antonetti; John Cardone; Enzo Bonmassar

In the last years small RNA molecules, i.e. microRNA (miRNA) encoded by miR genes, have been found to play a crucial role in regulating gene expression of a considerable part of plants and animals genome. Here, we report the essential information on biogenesis of miRNAs and recent evidence on their important role in human diseases. Emphasis has been given to miR-155, since this molecule represents a typical multifunctional miRNA. Recent data indicate that miR-155 has distinct expression profiles and plays a crucial role in various physiological and pathological processes such as haematopoietic lineage differentiation, immunity, inflammation, cancer, and cardiovascular diseases. Moreover, miR-155 has been found to be implicated in viral infections, particularly in those caused by DNA viruses. The available experimental evidence indicating that miR-155 is over expressed in a variety of malignant tumors allows us to include this miRNA in the list of genes of paramount importance in cancer diagnosis and prognosis. Exogenous molecular control in vivo of miR-155 expression could open up new ways to restrain malignant growth and viral infections, or to attenuate the progression of cardiovascular diseases.


Journal of Hematology & Oncology | 2012

MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status

Isabella Faraoni; Serena Laterza; Davide Ardiri; Claudia Ciardi; Francesco Fazi; Francesco Lo-Coco

BackgroundMicroRNA have a central role in normal haematopoiesis and are deregulated in acute myeloid leukaemia (AML). The purpose of the study was to investigate by qRT-PCR the expression of miRNAs involved in myeloid differentiation (miR-424, miR-155, miR-223, miR-17-5p) in 48 patients with cytogenetically normal AML well characterized for NPM1 and/or FLT3 mutations. Three types of normalization were used for the data validation.FindingsWe found that miR-424 was down-modulated in AMLs with NPM1mutA regardless of FLT3 status. On the contrary, miR-155 showed up-regulation in patients with FLT3 internal tandem duplications (ITD) with or without NPM1 mutations. No significant associations were found by analyzing miR-223 and miR-17-5p in relation to FLT3 and NPM1 status.ConclusionsThis study supports the view that major genetic subsets of CN-AML are associated with distinct miRNA signatures and suggests that miR-424 and miR-155 deregulation is involved in the pathogenesis of CN-AML with NPM1 and FLT3-ITD mutations, respectively.


Biochimica et Biophysica Acta | 2015

BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib

Isabella Faraoni; Mirco Compagnone; Serena Lavorgna; Daniela F. Angelini; Maria Teresa Cencioni; Eleonora Piras; Paola Panetta; Tiziana Ottone; Susanna Dolci; Adriano Venditti; Grazia Graziani; Francesco Lo-Coco

Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polymerase (PARP) inhibitor currently under investigation in patients with solid tumors. To study the clinical potential of olaparib as a single-agent for the treatment of acute myeloid leukemia (AML) patients, we analyzed the in vitro sensitivity of AML cell lines and primary blasts. Clinically achievable concentrations of olaparib were able to induce cell death in the majority of primary AML case samples (88%) and tested cell lines. At these concentrations, olaparib preferentially killed leukemic blasts sparing normal lymphocytes derived from the same patient and did not substantially affect the viability of normal bone marrow and CD34-enriched peripheral blood cells obtained from healthy donors. Most primary AML analyzed were characterized by low BRCA1 mRNA level and undetectable protein expression that likely contributed to explain their sensitivity to olaparib. Noteworthy, while PARP1 over-expression was detected in blasts not responsive to olaparib, phosphorylation of the histone H2AFX (γH2AX) was associated with drug sensitivity. As to genetic features of tested cases the highest sensitivity was shown by a patient carrying a 11q23 deletion. The high sensitivity of AML blasts and the identification of biomarkers potentially able to predict response and/or resistance may foster further investigation of olaparib monotherapy for AML patients unfit to conventional chemotherapy.


Leukemia Research | 1995

HSP70 production and inhibition of cell proliferation in Molt-4 T-cells after cell-to-cell transmission of HTLV-I: effect of PGA1.

Chiara D'Onofrio; Antonella Puglianiello; Carla Amici; Isabella Faraoni; Giulia Lanzilli; Enzo Bonmassar

Infection with HTLV-I is associated with leukemic transformation of mature CD4+ T lymphocytes. PGA1, a powerful inhibitor of tumour cell proliferation, can prevent the clonal expansion of HTLV-I-infected cells following acute infection of cord blood-derived mononuclear cells. Since the antiproliferative effect of PGA1 on HTLV-I transformed, chronically infected MT-2 cell line was associated with induction of HSP70, we have investigated the effect of PGA1 on cell cycle progression and HSP70 production in a leukemic T-cell line (Molt-4) shortly after exposure to HTLV-I in a cell-to-cell transmission model. Rate of cell proliferation and HSP70 expression were studied within one duplication cycle of Molt-4 cells after exposure to HTLV-I. Growth of both control and virus-exposed cultures was inhibited by treatment with PGA1 (4 micrograms/ml) and cell cycling was arrested preferentially at the G1/S interphase. Synthesis of HSP70 was induced within 3 h by PGA1 in control and virus-exposed Molt-4 cells and became undetectable from overnight onward, though the protein accumulated in the cells. The arrest of growth was observed from overnight up to 48 h so that treated cells almost missed one cycle. Interestingly, HSP70 transcript and protein persisted at remarkably high levels in Molt-4 cells exposed to HTLV-I in the absence of PGA1, showing that HSP70 expression can be directly activated during primary infection with this human retrovirus. Moreover, in these cocultures, treatment with PGA1 or heat shock was not able to increase further the elevated level of HSP70 found in untreated cocultures, suggesting that during the early period of the virus-transmission phase, HTLV-I could interfere with HSP70 induction by other inducers.


Cancer Immunology, Immunotherapy | 1993

Protective effect of interferon β on human T cell leukaemia virus type I infection of CD4+ T cells isolated from human cord blood

Beatrice Macchi; Isabella Faraoni; Antonio Mastino; Chiara D'Onofrio; Gianna Romeo; Enzo Bonmassar

The present study shows the effect of human interferon β (IFNβ) on the susceptibility of highly purified cord blood CD4+ T cells to infection with the human T cell leukaemia virus type I (HTLV-I). Unfractionated cord blood mononuclear cells (CBMC), or a separated CD4+ T cell subpopulation (CBCD4) were exposed to HTLV-I by cocultivation with a chronically infected virus-donor cell line. The results show that presence of proviral DNA as well as virus transcription was markedly reduced by IFNβ in both populations, indicating that this cytokine protects not only unfractionated CBMC but also purified CBCD4 cells from virus infection. Moreover IFNβ treatment caused 60%–80% inhibition of virus expression in CBCD4, assayed as the presence of virus core protein p19. This study demonstrates that IFNβ is able to inhibit HTLV-I infection of CBMC through a mechanism that does not necessarily involve cell-mediated natural or antigen-dependent immunity afforded by CBMC subpopulations distinct from targets of HTLV-I infection. Therefore it is reasonable to conclude that IFNβ has a direct protective effect on CBCD4, through induction of antiviral resistance/activity in target cells.


Oncotarget | 2017

Modulation of GDF11 expression and synaptic plasticity by age and training

Emanuela De Domenico; Giovanna D’Arcangelo; Isabella Faraoni; Mattia Palmieri; Virginia Tancredi; Grazia Graziani; Paola Grimaldi; Lucio Tentori

The Growth Differentiation Factor 11 (GDF11) has been controversially involved in the aging/rejuvenation process. To clarify whether GDF11 is differently expressed during aging, we have evaluated GDF11 levels in skeletal muscles and hippocampi of young and old mice, sedentary or subjected to a 12-weeks triweekly training protocol. The results of real-time PCR and Western blot analyses indicate that skeletal muscles of sedentary old mice express higher levels of GDF11 compared to young animals (p < 0.05). Conversely, in hippocampi no significant differences of GDF11 expression are detected. Analysis of long-term potentiation, a synaptic plasticity phenomenon, reveals that population spikes in response to a tetanic stimulus are significantly higher in sedentary young mice than in old animals (p < 0.01). Training induces a significant improvement of long-term potentiation in both young and old animals (p < 0.05), an increase (p < 0.05) of skeletal muscle GDF11 levels in young mice and a reduction of GDF11 expression in hippocampi of old mice (p < 0.05). Overall, data suggest that GDF11 can be considered an aging biomarker for skeletal muscles. Moreover, physical exercise has a positive impact on long-term potentiation in both young and old mice, while it has variable effects on GDF11 expression depending on age and on the tissue analyzed.


Pharmacological Research | 2007

Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro

Lorena Rossi; Enzo Bonmassar; Isabella Faraoni


Journal of General Virology | 1997

AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro

Beatrice Macchi; Isabella Faraoni; Jing Zhang; Sandro Grelli; Cartesio Favalli; Antonio Mastino; Enzo Bonmassar


Clinical Cancer Research | 1997

Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro

Isabella Faraoni; Mario Turriziani; G Masci; L De Vecchis; Jerry W. Shay; Enzo Bonmassar; Grazia Graziani


Clinical Cancer Research | 1999

Suppression of Telomerase, Reexpression of KAI1, and Abrogation of Tumorigenicity by Nerve Growth Factor in Prostate Cancer Cell Lines

Sandra Sigala; Isabella Faraoni; Daniela Botticini; Marcelo Paez-Pereda; Cristina Missale; Enzo Bonmassar; PierFranco Spano

Collaboration


Dive into the Isabella Faraoni's collaboration.

Top Co-Authors

Avatar

Enzo Bonmassar

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Grazia Graziani

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Beatrice Macchi

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Chiara D'Onofrio

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Antonella Puglianiello

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Francesco Lo-Coco

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Lucio Tentori

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Mario Turriziani

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Pedro Miguel Lacal

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge